Advancing ODT Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advancing ODT Technology
Orally disintegrating tablets (ODTs) continue to attract attention as an alternative to conventional oral dosage forms.


Pharmaceutical Technology


"Compressed tablet systems are based on conventional tableting technology and vary in their degree of hardness and friability," explains Rosie McLaughlin, director of product development at Catalent. "This variability results in varying disintegration characteristics depending on the exact materials and process used, but typically disintegration times are higher than for lyophilized ODT formulations." Also, friable products may require specific packaging considerations. Loosely compressed ODT tablets generally rely on water-soluble excipients and/or super disintegrants to achieve rapid disintegration (30–60 s) (5).

Advancing ODTs

In response to growing interest for ODTs, several companies are advancing production capabilities and technologies.

Catalent Pharma Solutions, for example, recently added "Zydis" ODT commercial manufacturing capability at its facility in Somerset, New Jersey. A commercial Zydis line was installed into a space in existing buildings, which had originally been designed to accommodate future expansion. The line will be operational in 2007, and commercial production from the site is anticipated in 2009 pending associated regulatory filings.

"The Zydis process involves the preparation of an aqueous solution or suspension, from which individual units are dosed and freeze-dried," explains McLaughlin."The liquid-dosing process ensures good dose uniformity and facilitates containment of the active ingredient. The freezing process then results in a network of ice crystals that are sublimed during lyophilization to produce a highly porous structure, which facilitates the rapid dispersion characteristics of the product," she says.


Select companies with orally disintegrating tablets technology.
McLaughlin says the key advantage of the lyophilization technology used in the Zydis manufacture is the highly porous structure and consequent extremely rapid dispersion achieved (typically less than 5 s). The formulations are generally simple, typically incorporating two structure-forming agents with the API, in a ratio optimized for each product, plus any additives specifically required such as flavors, sweeteners, or pH modifying agents.

In addition to conventional small molecules, the lyophilization process has also been shown to be suitable for the formulation of peptide and protein drug molecules. "Protein and peptide molecules are physically and chemically sensitive, and lyophilization processes are typically used in their manufacture owing to the relatively low stresses applied during processing (e.g. low temperatures)," says McLaughlin.

Several peptide and protein-based drugs use the Zydis ODT technology, including "Grazax, " a grass-pollen allergy vaccine by ALK-Abelló(Hoersholm, Denmark).

Catalent is providing commercial production of Grazax at its facility in Swindon, United Kingdom. In August 2007, Catalent reported that ALK-Abelló will fund a new production line for current and future tablet-based allergy products at Catalent's Swindon facility. Commercial production on the new line is expected to begin in 2010.

Eurand (Vandalia, Ohio) has partnered with GlaxoSmithKline (GSK, London) to develop an ODT formulation of an undisclosed compound. Last October, the companies signed a formulation development pact under which GSK is using Eurand's "AdvaTab" oral disintegration tablet technology and "Microcaps" taste-masking technology.

"The new formulation for GlaxoSmithKline dissolves in the mouth in approximately 30 seconds without water and without leaving a bitter or sour taste," said Eurand CEO Gearóid Faherty in a June 2007 release. GSK has started a registration bioequivalence study for the new formulation and will make a milestone payment of $1 million to Eurand in recognition of the initiation of this biostudy. GSK intends to file for marketing authorization in the United States by the end of 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here